Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2021

View Archived Issues

Keymed evaluates CM-310 in phase II for chronic rhinosinusitis with nasal polyposis

PEP-010 enters first-in-human study in solid tumors

iBio advances COVID-19 vaccine programs

Russia authorizes use of single-dose Sputnik Light COVID-19 vaccine

Sangamo Therapeutics patents chimeric antigen receptors targeting IL-23

Lead Pharma Holding presents new ERR-alpha inverse agonists

New TRPA1 antagonists identified at Boehringer Ingelheim

PTPN11 inhibitors discovered at Hangzhou Rex Pharmaceutical

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

UCB identifies antiepileptic compounds improving on padsevonil

Study of a new CAIX-targeting radiotracer, [99mTc]PHC-102, for SPECT imaging in ccRCC patients

SparingVision studies ocular gene therapy SPVN-06 in primates

GQ-127 shows in vitro and in vivo antitumor activity in uveal melanoma

Reduced galectin-3 observed in central serous chorioretinopathy

Allysta Pharmaceutical initiates first-in-human study of ALY-688-SR

Enrollment ongoing in phase II study of JNJ-40411813 as adjunctive therapy in epilepsy

NuBiyota starts phase II study of MET-2 in subjects with major depression

Enrollment begins in phase II study of NeoVax cancer vaccine in patients with CLL

Telix cleared in Australia to begin phase III study of TLX-591 for metastatic CRPC

KNP-301 tested in mouse models of AMD

VIP-236 demonstrates potent antitumor efficacy in xenograft models

China NMPA approves bevacizumab biosimiilar LY-01008

Preclinical data presented for the ocular anesthetic AG-920

Cantargia plans to study CAN-04 with carboplatin/gemcitabine in advanced TNBC

Phase III FIGARO-DKD cardiovascular outcomes study of finerenone meets primary endpoint

Findings bolster RAD51 as biomarker for DNA repair deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...